Trial Profile
A Phase 1b-2 study of Mitomycin-C / Capecitabine chemoradiotherapy combined with Ipilumimab and Nivolumab or Nivolumab monotherapy as bladder sparing curative treatment for muscle Invasive bladder Cancer: the CRIMI study
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 02 Nov 2022
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Capecitabine; Mitomycin
- Indications Bladder cancer; Carcinoma; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms CRIMI
- 01 Nov 2022 Results(n=26) assessing the safety and tolerability of of Chemoradiotherapy Combined with Nivolumab + Ipilimumab for the Curative Treatment of Muscle-invasive Bladder Cancer published in the European Urology
- 11 Aug 2022 Planned End Date changed from 1 Jan 2025 to 1 Jul 2026.
- 11 Aug 2022 Planned primary completion date changed from 1 Jan 2023 to 1 Jul 2024.